Stockscreener 앱 받기
71.21
0.85%
-0.61
전일 마감가:
$71.82
열려 있는:
$71.63
하루 거래량:
1.26M
Relative Volume:
0.58
시가총액:
$8.37B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
23.58
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-1.74%
1개월 성능:
+10.45%
6개월 성능:
+22.75%
1년 성능:
+28.61%
1일 변동 폭
$70.78
$71.83
1주일 범위
$70.75
$74.08
52주 변동 폭
$47.50
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
71.21 | 8.45B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen - Chartmill
Campbell & CO Investment Adviser LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
CEO Moves: How liquid is Halozyme Therapeutics Inc stockJuly 2025 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Halozyme Therapeutics (BIT:1HALO) Price Target Increased by 14.97% to 68.41 - Nasdaq
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity - Chartmill
Does Takeda’s ENTYVIO ENHANZE Deal Reshape The Bull Case For Halozyme Therapeutics (HALO)? - Sahm
Japan's Takeda partners with Halozyme to continue advancing Vedolizumab with ENHANZE® drug-delivery technology - BioSpectrum Asia
Trading Systems Reacting to (HALO) Volatility - Stock Traders Daily
Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy - Indian Pharma Post
Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correction2025 Dividend Review & Breakout Confirmation Alerts - Улправда
How Halozyme’s ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Moran Wealth Management LLC Grows Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains - Yahoo Finance
HALO or AXSM: Which Is the Better Value Stock Right Now? - Yahoo Finance
Halozyme, Takeda in arrangement to use former's drug delivery tech in Entyvio - MSN
Cardinal Capital Management Purchases Shares of 17,768 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Cerity Partners LLC Cuts Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Allspring Global Investments Holdings LLC Has $2.11 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How supply chain issues affect Halozyme Therapeutics Inc. stockPortfolio Risk Report & Consistent Profit Alerts - ulpravda.ru
Will Halozyme Therapeutics Inc. stock see insider buyingDividend Hike & Verified Technical Signals - ulpravda.ru
Is Halozyme Therapeutics Inc. stock ready for breakout2025 Key Highlights & Growth Focused Entry Reports - ulpravda.ru
Can Halozyme Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Review & Daily Momentum Trading Reports - ulpravda.ru
TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
TD Cowen Raises Price Target for HALO to $90.00, Maintains Buy Rating | HALO Stock News - GuruFocus
TD Cowen raises Halozyme Therapeutics stock price target to $90 on growth outlook - Investing.com Canada
Halozyme Partners with Takeda to Develop and Commercialize Vedolizumab - Contract Pharma
Halozyme Allows Takeda To Access Its ENHANZE Drug Delivery Technology For Use With Vedolizumab - Nasdaq
Takeda (TAK) Partners with Halozyme for Enhanced Drug Delivery - GuruFocus
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech - Investing.com
Halozyme signs licensing deal with Takeda for vedolizumab delivery tech By Investing.com - Investing.com Australia
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE - Chartmill
Why Halozyme Therapeutics Inc. stock remains undervaluedLarge Cap Stability Picks & Low Cost Capital Trading - Улправда
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 43% One-Year Surge? - Sahm
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Haloz - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (NASDAQ:HALO) Director Sells $140,500.00 in Stock - MarketBeat
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics, Skye Bioscience Collaborate to Evaluate Nimacimab for Obesity Treatment - marketscreener.com
Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology - Contract Pharma
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug By Investing.com - Investing.com Nigeria
Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Robust Revenue Growth and Strategic Partnerships Fuel Investor Optimism - DirectorsTalk Interviews
Should Halozyme’s Upgraded 2025 Revenue and Profit Guidance Reshape Expectations For Halozyme Therapeutics (HALO) Investors? - Sahm
Halozyme Therapeutics (HALO) Partners with Skye Bioscience for I - GuruFocus
Halozyme (HALO) Partners with Skye Bioscience for Obesity Treatm - GuruFocus
Halozyme and Skye partner on obesity drug delivery technology - Investing.com
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - The Manila Times
Halozyme Therapeutics (FRA:RV7) EV-to-OCF : 14.00 (As of Jan. 04, 2026) - GuruFocus
Cwm LLC Acquires 22,813 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER |
Jan 03 '26 |
Option Exercise |
0.00 |
7,611 |
0 |
38,424 |
4.73%
0.92%
자본화:
|
볼륨(24시간):